FDA OKs use of Varizig to ease effects of chickenpox

12/23/2012 | DoctorsLounge.com

Cangene's Varizig has been approved by the FDA to reduce the severity of chickenpox symptoms within four days after exposure to varicella zoster virus among individuals at high risk for chickenpox. High-risk patients include newborns, pregnant women, premature babies, children less than a year old, those with compromised immune systems and those without viral immunity, according to the agency.

View Full Article in:

DoctorsLounge.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY